Electroretinographic Effects of an Intravitreal Injection of Triamcinolone in Rabbit Retina | Ophthalmology | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Jonas  JDegenring  R Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular edema [in German].  Klin Monatsbl Augenheilkd 2002;219429- 432PubMedGoogle ScholarCrossref
Jonas  JBKreissig  ISofker  ADegenring  RF Intravitreal injection of triamcinolone for diffuse diabetic macular edema.  Arch Ophthalmol 2003;12157- 61PubMedGoogle ScholarCrossref
Martidis  ADuker  JSGreenberg  PB  et al.  Intravitreal triamcinolone for refractory diabetic macular edema.  Ophthalmology 2002;109920- 927PubMedGoogle ScholarCrossref
Massin  PAudren  FHaouchine  B  et al.  Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.  Ophthalmology 2004;111218- 225PubMedGoogle ScholarCrossref
Al-Haddad  CEJurdi  FABashshur  ZF Intravitreal triamcinolone acetonide for the management of diabetic papillopathy.  Am J Ophthalmol 2004;1371151- 1153PubMedGoogle ScholarCrossref
Karacorlu  MOzdemir  HKaracorlu  SAlacali  NMudun  BBurumcek  E Intravitreal triamcinolone as a primary therapy in diabetic macular oedema.  Eye 2005;19382- 386PubMedGoogle ScholarCrossref
Challa  JGillies  MPenfold  PGyory  JHunyor  ABillson  F Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.  Aust N Z J Ophthalmol 1998;26277- 281PubMedGoogle ScholarCrossref
Danis  RCiulla  TPratt  LAnliker  W Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.  Retina 2000;20244- 250PubMedGoogle ScholarCrossref
Jonas  JBAkkoyun  IBudde  WMKreissig  IDegenring  RF Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.  Arch Ophthalmol 2004;122218- 222PubMedGoogle ScholarCrossref
Jonas  JBDegenring  RFKreissig  IFriedemann  TAkkoyun  I Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study.  Eye 2005;19163- 170PubMedGoogle ScholarCrossref
Jonas  JBKreissig  IHugger  PSauder  GPanda-Jonas  SDegenring  R Intravitreal triamcinolone acetonide for exudative age related macular degeneration.  Br J Ophthalmol 2003;87462- 468PubMedGoogle ScholarCrossref
Ip  MS Intravitreal injection of triamcinolone: an emerging treatment for diabetic macular edema.  Diabetes Care 2004;271794- 1797PubMedGoogle ScholarCrossref
McCuen  BWBessler  MTano  YChandler  DMachemer  R The lack of toxicity of intravitreally administered triamcinolone acetonide.  Am J Ophthalmol 1981;91785- 788PubMedGoogle Scholar
Tano  YChandler  DMachemer  R Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.  Am J Ophthalmol 1980;90810- 816PubMedGoogle Scholar
Hida  TChandler  DArena  JEMachemer  R Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations.  Am J Ophthalmol 1986;101190- 195PubMedGoogle Scholar
Roth  DChieh  JSpirn  MGreen  SYarian  DChaudhry  N Noninfectious endophthalmitis associated with intravitreal triamcinolone injection.  Arch Ophthalmol 2003;1211279- 1282PubMedGoogle ScholarCrossref
Nelson  MTennant  MSivalingam  ARegillo  CBelmont  JMartidis  A Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection.  Retina 2003;23686- 691PubMedGoogle ScholarCrossref
Bakri  SJShah  AFalk  NSBeer  PM Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema.  Eye 2005;19686- 688PubMedGoogle ScholarCrossref
Ciardella  APKlancnik  JSchiff  WBarile  GLangton  KChang  S Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.  Br J Ophthalmol 2004;881131- 1136PubMedGoogle ScholarCrossref
Wenzel  AGrimm  CSeeliger  MW  et al.  Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor.  Invest Ophthalmol Vis Sci 2001;421653- 1659PubMedGoogle Scholar
Zemel  ELoewenstein  ALei  BLazar  MPerlman  I Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity.  Invest Ophthalmol Vis Sci 1995;361875- 1884PubMedGoogle Scholar
Lei  BPerlman  I The contributions of voltage- and time-dependent potassium conductances to the electroretinogram in rabbits.  Vis Neurosci 1999;16743- 754PubMedGoogle ScholarCrossref
Bush  RALei  BTao  W  et al.  Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology.  Invest Ophthalmol Vis Sci 2004;452420- 2430PubMedGoogle ScholarCrossref
Jamison  JABush  RALei  BSieving  PA Characterization of the rod photoresponse isolated from the dark-adapted primate ERG.  Vis Neurosci 2001;18445- 455PubMedGoogle ScholarCrossref
Kong  JGouras  P The effect of body temperature on the murine electroretinogram.  Doc Ophthalmol 2003;106239- 242PubMedGoogle ScholarCrossref
Mizota  AAdachi-Usami  E Effect of body temperature on electroretinogram of mice.  Invest Ophthalmol Vis Sci 2002;433754- 3757PubMedGoogle Scholar
Rufiange  MDumont  MLachapelle  P Correlating retinal function with melatonin secretion in subjects with an early or late circadian phase.  Invest Ophthalmol Vis Sci 2002;432491- 2499PubMedGoogle Scholar
Birch  DGBerson  ELSandberg  MA Diurnal rhythm in the human rod ERG.  Invest Ophthalmol Vis Sci 1984;25236- 238PubMedGoogle Scholar
Bush  RASieving  PA A proximal retinal component in the primate photopic ERG a-wave.  Invest Ophthalmol Vis Sci 1994;35635- 645PubMedGoogle Scholar
Newell  SWHainsworth  DPSanford  DAshton  P Clearance and metabolism of intravitreal triamcinolone [ARVO abstract].  J. Invest Ophthalmol Vis Sci 1993;34 ((suppl)) 1425Google Scholar
Stockton  RASlaughter  MM B-wave of the electroretinogram: a reflection of ON bipolar cell activity.  J Gen Physiol 1989;93101- 122PubMedGoogle ScholarCrossref
Hood  DCBirch  DG The a-wave of the human electroretinogram and rod receptor function.  Invest Ophthalmol Vis Sci 1990;312070- 2081PubMedGoogle Scholar
Lei  B The ERG of guinea pig (Cavis porcellus): comparison with I-type monkey and E-type rat.  Doc Ophthalmol 2003;106243- 249PubMedGoogle ScholarCrossref
Laboratory Sciences
November 1, 2005

Electroretinographic Effects of an Intravitreal Injection of Triamcinolone in Rabbit Retina

Author Affiliations

Author Affiliations: Mason Eye Institute (Drs Dierks, Lei, and Hainsworth) and Department of Veterinary Medicine and Surgery, College of Veterinary Medicine (Dr Lei and Mrs Zhang), University of Missouri–Columbia.

Arch Ophthalmol. 2005;123(11):1563-1569. doi:10.1001/archopht.123.11.1563

Objective  To investigate the clinical, histologic, and electroretinographic effects of intravitreal injection of triamcinolone acetonide suspension in the rabbit retina.

Methods  Three groups of 6 rabbits each received intravitreal injections. Group 1 received 4 mg of triamcinolone acetonide, group 2 received an equal volume (0.1 mL) of the corticosteroid supernatant, and group 3 received 4 mg of triamcinolone acetonide with the supernatant replaced with balanced salt solution. Uninjected left eyes served as controls. Electroretinograms were obtained at baseline and at 3 to 4 and 6 to 7 days after injection of triamcinolone. Enucleated eyes were examined histologically.

Results  Ocular examination revealed no differences among the 3 groups. When subjected to stimulation with moderate to high flash intensities, eyes that had received intravitreal injections of triamcinolone (groups 1 and 3) had a 10% to 25% increase in dark-adapted a- and b-wave electroretinographic amplitudes. No histologic differences were observed between injected and control eyes.

Conclusions  Intravitreal injection of 4 mg of triamcinolone acetonide does not cause a toxic reaction in the rabbit retina after 7 days. Triamcinolone therapy may augment the rod-driven electroretinographic responses, suggesting a mechanism by which visual function may improve.

Clinical Relevance  Evaluation of the toxic effects of triamcinolone is useful because of increased applications of intravitreal injection.